This site is part of the Informa Connect Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.

BIO-Europe Spring
March 18–20, 2024 | Barcelona, SpainMarch 26–27, 2024 | Digital Partnering

Allarta Life Science


Allarta is a pioneering biotechnology company, based in Canada, specializing in the development and production of advanced encapsulation technologies for the treatment of metabolic and inflammatory disorders, with a lead indication in Type 1 Diabetes. With a dedicated team of scientists, engineers and regulatory professionals, we are committed to revolutionising the field of diabetes treatment through our cutting-edge encapsulation solutions.
Key Highlights:•Cutting-Edge Encapsulation Technology: Allarta's immune-privileged hydrogel technology platform is 3D-printed and payload- and form-factor agnostic, enabling the effective delivery of primary or stem cell-derived therapeutic cells. With Allarta's technology, encapsulated islets and stem cells maintain best-in-class cell viability, functionality and persistence, with minimal fibrosis in preclinical animal models. Allarta also established novel cryoprotective products and stem cell encapsulation service.•Focus on Diabetes Treatment: At Allarta, we are driven by a mission to develop breakthrough encapsulation technologies that offers blood glucose control while providing independence from immune suppression to improve patients' quality of life. Our therapeutic devices demonstrated positive outcomes in terms of fibrosis and blood glucose control in allografts without immunosuppression in animal models. Allarta is currently in large animal studies with therapeutically relevant cell types, with a clear path to the clinic.Collaborative Partnerships: Allarta's achievements were recognized by the Canadian and International life science communities, including a JDRF IDDP in 2023. Future Growth and Expansion: Allarta continues to expand its product development and clinical translation teams, and is interested in exploring applications of our novel encapsulation technology in additional allogeneic cell therapy indications beyond T1D.